4BASEBIO UK SOCIETAS (4BB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has a cash flow conversion efficiency ratio of -0.703x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.11 Million ≈ $-865.08 USD) by net assets (GBX10.11 Million ≈ $1.23K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4BB market cap for the company's overall valuation and market capitalisation.
4BASEBIO UK SOCIETAS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how 4BASEBIO UK SOCIETAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
4BASEBIO UK SOCIETAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their cash flow conversion efficiency. See 4BB operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aminex PLC
LSE:AEX
|
-0.032x |
|
Octopus Aim Vct Plc
LSE:OOA
|
-0.006x |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
0.002x |
|
Story-I Ltd
AU:SRY
|
3.211x |
|
LUNGLIFE AI INC. DL-0001
F:9H4
|
N/A |
|
Marksmen Energy Inc
V:MAH
|
-0.009x |
|
Pacific Bay Minerals Ltd
V:PBM
|
0.110x |
|
1Spatial PLC
LSE:SPA
|
0.062x |
Annual Cash Flow Conversion Efficiency for 4BASEBIO UK SOCIETAS (2019–2025)
The table below shows the annual cash flow conversion efficiency of 4BASEBIO UK SOCIETAS from 2019 to 2025. View 4BASEBIO UK SOCIETAS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX10.11 Million ≈ $1.23K |
GBX-14.75 Million ≈ $-1.79K |
-1.459x | -258.21% |
| 2024-12-31 | GBX26.38 Million ≈ $3.21K |
GBX-10.74 Million ≈ $-1.31K |
-0.407x | -103.24% |
| 2023-12-31 | GBX-492.00K ≈ $-59.86 |
GBX-6.18 Million ≈ $-751.68 |
12.557x | +2000.62% |
| 2022-12-31 | GBX7.12 Million ≈ $866.30 |
GBX-4.70 Million ≈ $-572.34 |
-0.661x | -181.99% |
| 2021-12-31 | GBX11.70 Million ≈ $1.42K |
GBX-2.74 Million ≈ $-333.38 |
-0.234x | -254.37% |
| 2020-12-31 | GBX15.46 Million ≈ $1.88K |
GBX-1.02 Million ≈ $-124.35 |
-0.066x | -146.45% |
| 2019-12-31 | GBX-1.89 Million ≈ $-229.96 |
GBX-269.00K ≈ $-32.73 |
0.142x | -- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more